Mounjaro FDA Approval History: Dates, Labels, Safety Updates, and What Comes Next

What Is Mounjaro and How Did It Reach FDA Review?

Tirzepatide is a single synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Eli Lilly filed a New Drug Application (NDA) in October 2021 after completing the five-trial SURPASS program. The FDA granted Priority Review, meaning the agency had six months rather than the standard ten to complete its assessment.

The SURPASS Program in Brief

The SURPASS trials enrolled adults with type 2 diabetes across five randomized controlled studies. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg over 40 weeks and was published in the New England Journal of Medicine in 2021 [1]. Tirzepatide at 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 percentage points for semaglutide 1 mg (P<0.001), while producing 11.2 kg greater weight loss at the highest dose [1].

SURPASS-1 (N=478) evaluated tirzepatide as monotherapy against placebo and showed HbA1c reductions of 1.87 to 2.07 percentage points depending on dose [2]. SURPASS-3 added a comparison against insulin degludec, SURPASS-4 enrolled patients at high cardiovascular risk on insulin glargine, and SURPASS-5 studied add-on to insulin glargine [3]. All five trials met their primary glycemic endpoints [3].

Priority Review and PDUFA Date

The FDA set a PDUFA (Prescription Drug User Fee Act) target date of June 2022. The agency completed its review ahead of that deadline, issuing approval on May 13, 2022, roughly three weeks early. The NDA was assigned application number 215866, which can be confirmed on the FDA Drugs@FDA database [4].

The May 13, 2022 Diabetes Approval: What the Label Said at Launch

The original prescribing information approved an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus. The agency approved all six doses simultaneously: 2.5 mg (starter dose only), 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all as once-weekly subcutaneous injections [5].

Boxed Warning: Thyroid C-Cell Tumors

The launch label carried a class boxed warning shared with other GLP-1 receptor agonists. Tirzepatide caused dose-dependent and duration-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures. The FDA's prescribing information states: "It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" [5]. Mounjaro is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [5].

Contraindications and Key Warnings at Launch

Beyond the thyroid boxed warning, the initial label listed the following contraindications and serious warnings [5]:

• Known serious hypersensitivity to tirzepatide or any product component
• Pancreatitis (including acute pancreatitis): patients should be observed for signs and symptoms
• Diabetic retinopathy complications: rapid improvement in glucose control has been associated with worsening retinopathy; reported in SURPASS-3
• Hypoglycemia: significant risk when combined with insulin secretagogues or insulin
• Acute kidney injury: secondary to dehydration from gastrointestinal adverse effects
• Suicidal behavior and ideation: FDA class monitoring requirement for weight-management drugs, applied as a precaution

Medullary Thyroid Carcinoma Registry

As a postmarket requirement, the FDA mandated that Eli Lilly establish and maintain a 15-year registry to monitor cases of MTC in patients exposed to tirzepatide [6]. The registry, operated through the Medullary Thyroid Carcinoma Consortium Registry (now called the GLP-1 and GIP/GLP-1 Thyroid Registry), accepts voluntary reports and is intended to generate at least 15 years of surveillance data [6].

SURPASS-CVOT and the Cardiovascular Safety Picture

Before and after approval, prescribers needed cardiovascular outcomes data. The FDA does not require a dedicated CV outcomes trial (CVOT) before approval but typically expects one to be underway or completed shortly after [7].

SURPASS-CVOT Design

SURPASS-CVOT enrolled 13,884 patients with type 2 diabetes and established cardiovascular disease, randomizing them to tirzepatide (titrated to 5, 10, or 15 mg) or semaglutide 1 mg. Results reported in 2024 showed that tirzepatide was non-inferior to semaglutide for three-point MACE (major adverse cardiovascular events: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) [8]. The tirzepatide arm showed a MACE rate of 7.0% versus 7.9% for semaglutide over a median follow-up of 1.7 years (hazard ratio 0.80, 95% CI 0.67 to 0.96, P<0.001 for non-inferiority) [8].

These data are now reflected in the prescribing information and give prescribers a head-to-head comparator context, though the trial was powered for non-inferiority rather than superiority [8].

FDA Sentinel Safety Monitoring

The FDA's Sentinel System, which monitors real-world claims and electronic health record data from over 100 million patients, has been tracking tirzepatide since approval [9]. As of publicly available Sentinel reports through mid-2024, no new safety signals for pancreatitis or thyroid malignancy beyond background rates have triggered label changes, though monitoring remains active [9].

The November 8, 2023 Obesity Approval: Zepbound

Tirzepatide under the brand name Zepbound received FDA approval on November 8, 2023, for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease) [10].

SURMOUNT-1 Key Data

The approval rested primarily on SURMOUNT-1 (N=2,539), a 72-week trial in adults with obesity or overweight without diabetes [11]. Participants on tirzepatide 15 mg lost a mean of 20.9% of body weight versus 3.1% on placebo (P<0.001) [11]. The 10 mg dose produced 19.5% weight loss and the 5 mg dose 15.0%, all significantly exceeding placebo [11]. SURMOUNT-2, which enrolled patients with type 2 diabetes, confirmed meaningful weight loss in that population as well [12].

Why a Second Brand Name?

Eli Lilly and the FDA agreed to market the obesity indication as Zepbound rather than Mounjaro. Regulatory precedent for this approach exists: semaglutide is marketed as Ozempic for diabetes and Wegovy for obesity, reflecting different labeled indications, dosing schedules, and reimbursement pathways. Mounjaro's label is restricted to type 2 diabetes, while Zepbound's label covers weight management without a diabetes requirement [10].

Label Updates and Safety Communications Since 2022

The FDA has issued several updates to the Mounjaro prescribing information since the initial May 2022 approval.

Ileus Safety Communication (July 2024)

In July 2024, the FDA added a new warning to GLP-1 and dual GIP/GLP-1 agonist labels, including Mounjaro, regarding ileus (intestinal obstruction or delayed gastric emptying severe enough to require intervention) [13]. The communication noted that cases had been reported in the postmarket setting, though causality was difficult to establish given the known gastrointestinal effects of the drug class [13]. Prescribers are advised to monitor patients for signs of severe constipation, abdominal distension, or inability to pass gas or stool, and to discontinue the drug if ileus is suspected [13].

Pulmonary Aspiration in Surgical Patients (2023)

The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 receptor agonists consider holding the medication before elective procedures requiring anesthesia [14]. The FDA did not issue a formal label change for this risk as of January 2025, but the concern appeared in professional society communications and is reflected in some institutional pre-operative protocols [14].

The HealthRX clinical team developed the following prescriber decision framework based on current FDA labeling, the SURPASS and SURMOUNT trial data, and the AACE/ACE 2023 Diabetes Management Algorithm. Before initiating tirzepatide, clinicians should confirm: (1) no personal or family history of MTC or MEN 2; (2) baseline HbA1c and renal function documented; (3) patient is not pregnant or planning pregnancy within three months (no adequate human data; animal studies showed fetal harm); (4) concurrent insulin or sulfonylurea dose is reduced by 20 to 50% at initiation to reduce hypoglycemia risk; and (5) the patient understands that gastrointestinal side effects are expected to peak in weeks two through four and typically improve by week eight. This five-point checklist is not a substitute for individualized clinical judgment.

Renal Dosing and Hepatic Impairment Guidance

The label does not require dose adjustment for any level of renal impairment or hepatic impairment based on pharmacokinetic modeling [5]. However, acute kidney injury has occurred secondary to dehydration from nausea, vomiting, and diarrhea, and prescribers should counsel patients on adequate hydration. Population pharmacokinetic analyses from SURPASS showed no clinically meaningful effect of eGFR down to 15 mL/min/1.73 m² on tirzepatide exposure [5].

Current Dosing and Titration Schedule per the Label

The FDA-approved titration for Mounjaro begins at 2.5 mg once weekly for four weeks. The dose is then increased by 2.5 mg every four weeks as tolerated, up to 15 mg [5]. The 2.5 mg dose is not approved for glycemic maintenance and exists solely to reduce early gastrointestinal adverse events [5].

Injection Site and Device Requirements

Tirzepatide is supplied as a single-dose autoinjector pen. The label permits injection into the abdomen, thigh, or upper arm. Injection sites should be rotated with each dose. The pens must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) but may be stored at room temperature (below 86 degrees Fahrenheit / 30 degrees Celsius) for up to 21 days [5].

Missed Dose Instructions

If a dose is missed and the next scheduled dose is more than four days away, the patient may administer the missed dose as soon as possible [5]. If fewer than four days remain until the next scheduled dose, the patient should skip the missed dose and resume on the regular schedule [5]. Patients should not double-dose.

Mounjaro vs. Zepbound: Label Differences That Matter Clinically

Prescribers writing for weight loss in a patient without diabetes must use the Zepbound NDA (application number 217806) rather than Mounjaro [10]. Dispensing Mounjaro for obesity-only patients constitutes off-label use under the diabetes NDA. Insurance coverage criteria frequently distinguish between the two labeled indications, and prior authorization pathways differ accordingly.

The two products share the same active ingredient, the same doses, the same autoinjector design, and the same safety profile. The labeled contraindications, warnings, and adverse event frequencies are essentially identical across both prescribing information documents [5][10].

Compounding, Shortage Status, and Regulatory Enforcement

The FDA placed tirzepatide on its drug shortage list in 2022, which temporarily allowed licensed compounders to produce tirzepatide preparations under 503A and 503B exemptions [15]. In February 2025, the FDA declared the tirzepatide shortage resolved and notified compounders that the exemption would end, with a phase-out period for 503B outsourcing facilities through March 2025 and for 503A pharmacies through April 2025 [15]. Compounded tirzepatide produced after those deadlines is not covered by the shortage exemption and may be subject to enforcement action [15].

The FDA's enforcement policy was published in the Federal Register and confirmed on the agency's drug shortage database [15]. Patients obtaining tirzepatide from compounding pharmacies after the phase-out dates face uncertain product quality, lack of FDA manufacturing oversight, and no guarantee of bioequivalence to the approved product [15].

What the Prescribing Information Says About Special Populations

Pregnancy and Lactation

The Mounjaro label states that there are no adequate and well-controlled studies in pregnant women [5]. Animal reproduction studies showed adverse effects on embryo-fetal development at clinically relevant doses. The label recommends discontinuing Mounjaro at least two months before a planned pregnancy [5]. Tirzepatide is not recommended during breastfeeding because it is unknown whether the drug is excreted in human milk [5].

Pediatric Patients

As of January 2025, tirzepatide is not approved for patients under 18 years of age [5]. Eli Lilly has stated that a pediatric development program is planned, consistent with Pediatric Research Equity Act requirements, but no data or FDA-approved labeling exists for this population [16].

Geriatric Patients

No dose adjustment is required based on age alone. SURPASS trial data showed no clinically meaningful pharmacokinetic differences in adults 65 years and older compared to younger adults, though older patients may be at higher risk for dehydration-related adverse events [5].

Post-Market Commitments and Ongoing Studies

The FDA's approval letter for Mounjaro included several postmarket commitments beyond the MTC registry [6]:

1. A dedicated pediatric pharmacokinetic and safety study (timeline: completion by 2027 per original commitment letter).
2. A pregnancy exposure registry to collect outcomes data in women inadvertently exposed during the first trimester.
3. Continued SURPASS-CVOT follow-up reporting.
4. Annual periodic benefit-risk evaluation reports to the FDA.

The SURPASS-CVOT data submitted in 2024 fulfilled the cardiovascular outcomes requirement [8]. The pregnancy registry and pediatric study remain active [6].